GSA Capital Partners LLP Sells 257,715 Shares of DURECT Co. (NASDAQ:DRRX)

GSA Capital Partners LLP lessened its stake in DURECT Co. (NASDAQ:DRRX) by 86.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,790 shares of the specialty pharmaceutical company’s stock after selling 257,715 shares during the quarter. GSA Capital Partners LLP owned approximately 0.13% of DURECT worth $56,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Richmond Brothers Inc. lifted its stake in DURECT by 39.5% during the 2nd quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock valued at $1,383,000 after acquiring an additional 303,670 shares in the last quarter. International Assets Investment Management LLC lifted its position in shares of DURECT by 41.3% during the second quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock valued at $28,000 after purchasing an additional 6,300 shares in the last quarter. Finally, Accredited Investors Inc. purchased a new position in DURECT during the second quarter worth about $113,000. Hedge funds and other institutional investors own 28.03% of the company’s stock.

DURECT Stock Performance

NASDAQ DRRX opened at $0.97 on Tuesday. The company has a market capitalization of $30.11 million, a PE ratio of -1.59 and a beta of 1.13. DURECT Co. has a 52-week low of $0.48 and a 52-week high of $1.88. The company has a 50-day simple moving average of $1.28 and a 200 day simple moving average of $1.36.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. HC Wainwright reissued a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th. StockNews.com began coverage on DURECT in a report on Tuesday, November 19th. They set a “sell” rating on the stock.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.